Background: Most of the available literature on ST-Elevated myocardial infarction (STEMI) in women was conducted in the developed world and data from Middle-East countries was limited.
Aims: To examine the clinical presentation, patient management, quality of care, risk factors and inhospital outcomes of women with acute STEMI compared with men using data from a large STEMI registry from the Middle East.
Methods: Data were derived from the third Gulf Registry of Acute Coronary Events (Gulf RACE-3Ps), a prospective, multinational study of adults with acute STEMI from 36 hospitals in 6 Middle-Eastern countries. The study included 2928 patients; 296 women (10.1%) and 2632 men (89.9%). Clinical presentations, management and in-hospital outcomes were compared between the 2 groups.
Results: Women were 10 years older and more likely to have diabetes mellitus, hypertension, and hyperlipidemia compared with men who were more likely to be smokers (all p<0.001). Women had longer median symptom-onset to emergency department (ED) arrival times (230 vs. 170 min, p<0.001) and ED to diagnostic ECG (8 vs. 6 min., p<0.001). When primary percutaneous coronary intervention (PPCI) was performed, women had longer door-to-balloon time (DBT) (86 vs. 73 min., p=0.009). When thrombolytic therapy was not administered, women were less likely to receive PPCI (69.7 vs. 76.7%, p=0.036). The mean duration of hospital stay was longer in women (6.03 ± 22.51 vs. 3.41 ± 19.45 days, p=0.032) and the crude in-hospital mortality rate was higher in women (10.4 vs. 5.2%, p<0.001). However, after adjustments, multivariate analysis revealed a statistically non-significant trend of higher inhospital mortality among women than men (6.4 vs. 4.6%), (p=0.145).
Conclusion: Our study demonstrates that women in our region have almost double the mortality from STEMI compared with men. Although this can partially be explained by older age and higher risk profiles in women, however, correction of identified gaps in quality of care should be attempted to reduce the high morbidity and mortality of STEMI in our women.
Keywords: ST-elevated myocardial infraction, acute coronary syndrome, percutaneous coronary intervention, quality of care, mortality, Middle-East.
The Role of Hyperglycaemia and the Hypercoagulable State in the Pathogenesis of Cardiovascular Events in Diabetes Mellitus: Implications for Hypertension Management
Current Pharmaceutical Design Evaluation of Risk Factors Associated with Diabetic Foot Ulcers in Saudi Arabia
Current Diabetes Reviews Advancements in the Anti-Diabetes Chemotherapeutics Based on Amino Acids, Peptides, and Peptidomimetics
Mini-Reviews in Medicinal Chemistry Clinical Use of Real-Time Continuous Glucose Monitoring
Current Diabetes Reviews Sodium-glucose Cotransporter 2 Inhibitors and the Risk of Diabetic Ketoacidosis; from Pathophysiology to Clinical Practice
Cardiovascular & Hematological Disorders-Drug Targets Early Apoptotic Vascular Signaling is Determined by Sirt1 Through Nuclear Shuttling, Forkhead Trafficking, Bad, and Mitochondrial Caspase Activation
Current Neurovascular Research The Management of Dyslipidaemia in Patients with Type 2 Diabetes Mellitus Receiving Lipid-Lowering Drugs: A Sub-Analysis of the CEPHEUS Findings
Current Vascular Pharmacology Angiotensin II in Type 2 Diabetes Mellitus
Current Protein & Peptide Science Sulfur- and Acyl Chain-Dependent Influence of 2-Methoxy-Lysophosphatidylcholine Analogues on β Pancreatic Cells
Current Topics in Medicinal Chemistry The Role of Antiplatelet Therapy in Primary Prevention. A Review
Current Pharmaceutical Design Renin-Angiotensin-Aldosterone System Antagonists and the Prevention of Type 2 Diabetes Mellitus
Current Pharmaceutical Design Neck Circumference and its Correlation to Other Anthropometric Parameters and Finnish Diabetes Risk Score (FINDRISC)
Current Diabetes Reviews Targeting Peroxisome Proliferator-Activated Receptor Gamma for Generation of Antidiabetic Drug
Current Diabetes Reviews Interleukin-25: Key Regulator of Inflammatory and Autoimmune Diseases
Current Pharmaceutical Design Incidence of Type 2 Diabetes Among Patients Exposed to the Combination of Pravastatin and Paroxetine
Current Drug Safety Mechanisms Involved in Glycemic Control Promoted by Exercise in Diabetics
Current Diabetes Reviews Insulin Resistance in Brain and Possible Therapeutic Approaches
Current Vascular Pharmacology The Need for Physiologically Relevant Peroxisome Proliferator-Activated Receptor-gamma (PPAR-γ) Ligands
Endocrine, Metabolic & Immune Disorders - Drug Targets SHIP2: An Emerging Target for the Treatment of Type 2 Diabetes Mellitus
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Diabetes-Related Neurological Implications and Pharmacogenomics
Current Pharmaceutical Design